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Abstract 
Metabolic pathways which extract energy from carbon compounds are essential for an organism’s 
survival.  Therefore, inhibition of enzymes in these pathways represents a potential therapeutic 
strategy to combat parasitic infections.  However, the high degree of similarity between host and 
parasite enzymes makes this strategy potentially difficult.  Nevertheless, several existing drugs to 
treat infections by parasitic helminths (worms) target metabolic enzymes.  These include the 
trivalent antimonials which target phosphofructokinase and Clorsulon which targets 
phosphoglycerate mutase and phosphoglycerate kinase.  Glycolytic enzymes from a variety of 
helminths have been characterised biochemically, and some inhibitors identified.  To date none of 
these inhibitors have been developed into therapies.  Many of these enzymes are externalised from 
the parasite and so are also of interest in the development of potential vaccines.  Less work has been 
done on tricarboxylic acid cycle enzymes and oxidative phosphorylation complexes.  Again, while 
some inhibitors have been identified none have been developed into drug-like molecules.  Barriers 
to the development of novel drugs targeting metabolic enzymes include the lack of experimentally 
determined structures of helminth enzymes, lack of direct proof that the enzymes are vital in the 
parasites and lack of cell culture systems for many helminth species.  Nevertheless, the success of 
Clorsulon (which discriminates between highly similar host and parasite enzymes) should inspire us 
to consider making serious efforts to discover novel anthelminthics which target metabolic enzymes. 
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Introduction:  the need for new drugs to combat helminth infections 
Infections with helminth (worm) parasites are a major burden on humanity.  It is estimated that 
approximately one third of the human population are currently infected with parasitic helminths [1].  
The majority of these individuals live in developing countries and the infections are classed as 
neglected tropical diseases.  Many of these individuals are infected with several helminths or with 
other infectious agents such as HIV, the malarial parasite or bacteria [2].  In many cases, the 
helminth infections are not immediately life-threatening.  However, in general, they result in 
significant ill health and may have longer term consequences even if the actual infection is cleared.  
The consequences are not just felt by the infected individuals:  reduced productivity of those 
infected can have drastic consequences for families and communities.  This is, perhaps, especially 
severe in largely agricultural communities which rely heavily on human labour.  There is also a world-
wide burden on farm animals.  Again, this reduces productivity and, consequently, income.  Almost 
twenty years ago, the costs of helminth infections to agriculture in Australia was estimated at one 
billion US dollars [3].  The current, global cost is likely to be many times that amount. 
The main groups of helminth parasites of importance to mammals are from the phyla 
Platyhelminthes (flat worms) and Nematoda (round worms).  Within the Platyhelminthes the 
trematoda (flukes) and cestoda (tapeworms) are the most important classes and within Nematoda 
soil transmitted and filarial nematodes are the most important groups.  By numbers of humans 
infected, the roundworm Ascaris lumbricoides is the most significant with an estimated 807 million 
people infected [1].  Whipworms (Trichuris trichiura) and hookworms (Necator americanus and 
Ancylostoma duodenale) each infect in excess of 500 million people [1].  Among the trematodes, the 
blood flukes (Schistosoma spp.) infect over 200 million people and are second only to the malarial 
parasites in terms of number of humans killed globally each year [1, 4, 5].  Many of these parasitic 
infections are zoonotic, being passed to humans from domestic animals [6]. 
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To date, there are no effective vaccines for helminth infections and treatment relies entirely on 
chemotherapy.  While many anthelminthic drugs (e.g. triclabendazole, praziquantel) are cheap, 
effective and generally considered safe, not all diseases can be treated effectively.  Resistance to 
these drugs is also emerging.  Resistance to the triclabendazole (the treatment of choice for Fasciola 
spp infections) has been documented in many countries in farm animals [7-14].  Recently the first 
confirmed case of a human infected with triclabendazole resistant F. hepatica has been reported 
[15].  Although resistance to praziquantel (used to treat Schistosoma spp infections) has not been 
conclusively demonstrated in the field, it has been shown to occur under laboratory conditions [16, 
17].  Ivermectin (a broad spectrum anthelminthic) resistance has also been documented [18-22].  
There is even resistance to drugs which have been relatively recently introduced.  Monepantel is a 
broad spectrum drug for the treatment of nematode infections in livestock.  It was introduced in 
2009 and resistant isolates have already been reported [23].  The emergence of resistance to these 
drugs is not surprising and its further spread should be expected.  Although it may be slowed by 
improved dosing and prescribing policies, it will not be stopped.  Resistance is an almost inevitable 
evolutionary response by the organism once it is placed under severe selective pressure by the 
widespread use of anthelminthic drugs.  While longer term solutions may come from the use of 
vaccines or improved living conditions in the developing world, the immediate need is for new drugs 
[24]. 
 
The potentials and pitfalls of targeting metabolic enzymes 
Central carbon metabolism (glycolysis, Krebs’ tricarboxylic acid cycle, the electron transport chain 
and associated pathways) is necessary for energy production in the majority of eukaryotes.  
Inhibition of these processes generally results in reduced ATP production and can lead to cell death.  
A number of common poisons target elements of carbon metabolism.  For example, cyanide ions 
inhibit cytochrome coxidase and arsenate ions can substitute for phosphate ions reducing the ATP 
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yield from glycolysis and the tricarboxylic (citric) acid cycle (TCA) [25, 26].  These toxins have broad 
species specificity and affect the majority of organisms tested.  Consequently, they have no potential 
in the treatment of pathogens such as helminth parasites.  Nevertheless, the effectiveness of these 
toxins suggests that inhibition of enzymes in these metabolic pathways is likely to result in death of 
the parasite. 
Further evidence for the critical importance of carbon metabolism comes from inherited metabolic 
diseases resulting from mutations in the genes encoding enzymes from these pathways.  These 
diseases tend to be rare, but the symptoms are often severe.  Examples include triose phosphate 
isomerase deficiency (OMIM #615512), phosphoglycerate kinase 1 deficiency (OMIM # 300653), 
hereditary fructose intolerance (aldolase B deficiency; OMIM #22960) and classic galactosemia 
(galactose 1-phosphate uridylyltransferase deficiency; OMIM #230400) [27-31].  In addition to 
reduced energy production, these diseases often have additional phenotypes.  For example, 
triosephosphate isomerase deficiency results in a build-up of dihydroxyacetone phosphate which is 
believed to be toxic, a result which is recapitulated by inhibitors of the enzyme [27, 32].  Therefore, 
it is expected that inhibition of key metabolic enzymes in helminth pathogens would lead to 
numerous deleterious pharmacological effects which would kill (or severely harm) the organism. 
The pathways of carbon metabolism are highly conserved through evolution, as are the enzymes 
which catalyse the individual steps.  Thus, there are few structural differences between the host and 
parasite enzymes which can be exploited for the design of species-specific inhibitors.  For example, 
the crystal structures of human and S. mansoni hexokinase I have a root mean squared deviation of 
approximately 1 Å [33].  Nevertheless, there was considerable interest in the 1950s, 1960s and 
1970s in studying the metabolic pathways and enzymes of parasites.  This interest was, in part, 
motivated by a desire to discover biochemical or structural differences between host and parasite 
enzymes which could be exploited in drug discovery.  Over the subsequent two to three decades 
interests waned and only in the last 10 or so years has this interest in helminth metabolic enzymes 
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recovered.  The loss of interest coincided with the widespread use of highly effective anthelminthics 
such as praziquantel and triclabendazole.  The re-emergence of interest coincided with the 
realisation that resistance to these compounds is a growing threat and to increased interest in 
targeting metabolism in other pathogens and in cancer [34-39]. 
Prior to the discovery of praziquantel, the main treatment for schistosome infections was antimony-
based compounds.  These treatments were somewhat unsatisfactory since they cause considerable 
side-effects in the patient [40].  These trivalent organic antimonials (e.g. Stibophen, Scheme 1) target 
the glycolytic enzyme phosphofructokinase (PFK, EC 2.7.1.11) [41, 42].  A similar mechanism, 
combined with inhibition of a second enzyme, aldolase occurs in filarial worms [43].  The use of 
these compounds in schistosomiasis has been largely superseded by praziquantel.  They are still 
used to treat leishmaniasis.  However, the mode of action in Leishmania spp is believed to involved 
disruption of nucleotide metabolism rather than effects on glycolysis [44, 45]. 
Clorsulon (MK-401, 4-amino-6-trichloroethenyl 1,3-benzenedisulfonamide; Scheme 1) is used to 
treat farm animals infected with Fasciola spp [46, 47].  Its mode of action is the selective, 
competitive inhibition of the glycolytic enzymes phosphoglycerate kinase (EC 2.7.2.3) and 
phosphoglyceromutase (EC 5.4.2.11) [48-51].  It also has weak activity against carbonic anhydrase 
(EC 2.4.1.1) in the host and, most likely, the parasite [52, 53].  The drug causes widespread damage 
to the ultrastructure of F. hepatica [54-57]. 
The broad spectrum benzimidazole anthelminthic mebendazole (Scheme 1) has been shown to 
inhibit the TCA enzyme malate dehydrogenase (EC 1.1.1.37) from Ascaris suum, Fasciola hepatica 
and Moniezia expansa [58].  Two related compounds, fenbendazole and thiabendazole (Scheme 1) 
inhibit the malate dehydrogenase of Trichuris globulosa.  In addition, these compounds also inhibit 
glucose 6-phosphate dehydrogenase (EC 1.1.1.49) and triacylglycerol lipase (EC 3.1.1.3) from this 
species [59].  The main target of benzimidazoles is generally considered to be the cytoskeletal 
protein β-tubulin [60].  It remains to be discovered how significant the inhibition of metabolic 
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enzymes is in their overall mode of action.  Nevertheless, the existence of these examples of proven 
anthelminthics which target metabolic enzymes suggests that there is considerable scope for further 
advances in this area. 
Although the main pathways of carbon metabolism, and the enzymes which catalyse the individual 
steps, show high similarity between the parasites and hosts, there are some metabolic adaptations 
which are unique to the parasites.  Most likely, these reflect the life cycles of the worms.  In general, 
these life cycles involve an intermediate, invertebrate host (often a snail or other mollusc) as well as 
the definitive, mammalian host.  In addition, there may be free-living stages.  This means that the 
parasite must adjust to a range of temperatures and oxygen levels [61].  Thus, we would expect that 
helminth parasite enzymes should be able to be active over wider temperature ranges than the 
host’s (or that helminths would be able to express different isoenzymes which are adapted to 
particular temperature conditions).  Unlike the hosts, the parasite must be able to survive for 
extended periods under anaerobic conditions.  Most eukaryotic species rely largely on glycolytic ATP 
production under low oxygen conditions.  In mammals, this can only be sustained for short periods 
of time since the energy yield is too low and lactate levels increase, altering the pH of the blood [62]. 
Many helminth parasites have adaptations to their metabolic pathways which permit increased ATP 
production under anaerobic conditions.  The TCA is modified so that part of it can run partly “in 
reverse” (Figure 1) [63].  In F. hepatica, phosphoenolpyruvate is carboxylated and reduced, 
converting it to malate.  This conversion occurs in the cytoplasm and the malate is transported to 
the mitochondrial matrix.  Similar reactions occur in most aerobic organisms to replenish TCA 
intermediates when the cycle is used for biosynthesis rather than energy production.  In the fluke, 
there are two fates of the mitochondrial malate [64].  Some molecules are oxidatively 
decarboxylated to pyruvate, which is subsequently converted to acetyl coenzyme A [65, 66].  This 
process produces two molecules of NADH.  The acetyl coenzyme A then reacts with succinate 
releasing acetate and generating succinyl coenzyme A.  Conversion of this succinyl coenzyme A to 
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succinate is coupled to the direct production of ATP (Figure 1) [67-69].  The remaining malate 
molecules are reduced to succinate (via fumarate) in a reversal of the TCA reactions.  The production 
of succinate is catalysed by fumarate reductase (EC 1.3.5.4), rather than succinate dehydrogenase 
(EC 1.3.5.1), the enzyme which catalyses the “forward” reaction under aerobic conditions.  The 
succinate reacts with propionyl coenzyme A to generate methylmalonyl coenzyme A (via succinyl 
coenzyme A).  The regeneration of propionyl coenzyme A from this compound is coupled to the 
production of one molecule of ATP [70, 71].  Thus, under anaerobic conditions the fluke is able to 
dismutate malate, producing ATP without net oxidation or reduction (Figure 1).  Further ATP is 
produced from coupling the reduction catalysed by fumarate reductase to an electron transport 
chain [61, 63, 72].  The electrons required for this reaction are provided by reduced rhodoquinone, 
generated by a modified form of mitochondrial complex I.  In the fluke and under anaerobic 
conditions, complex I transfers electrons from NADH to rhodoquinone and couples this reaction to 
the transport of protons across the inner mitochondrial membrane [73].  This generates a proton 
motive force and enables the synthesis of a limited amount of ATP, even in the absence of oxygen 
(Figure 1).  Rhodoquinone (Scheme 2) is a mobile, low redox potential electron carrier found in 
helminths (and some bacteria) which are able to generate proton motive forces in the absence of a 
terminal electron acceptor such as oxygen [73-77].  The synthetic pathway for rhodoquinone 
appears to be very similar to that of ubiquonone; indeed, it has been speculated that only the final 
reaction differs [78]. 
Although F. hepatica remains one of the best characterised helminth parasites in terms of its 
anaerobic metabolic adaptations, similar pathways have been demonstrated or inferred in a variety 
of other species.  These include the trematodes Schistosoma mansoni [79], Calicophoron ijimai [80] 
and Paragonimus westermani [81], the nematodes Ascaris suum [82-85], Setaria digitata [86] and 
Haemonchus contortus [87] and the cestodes Spirometra mansonoides (Diphyllobothrium 
mansonoides) [88], Hymenolepis diminuta [89], Hymenolepis microstoma [90] and Taenia crassiceps 
[91]. 
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Helminth glycolytic enzymes:  current state of knowledge 
Although genome sequences are available for some helminths, our level of knowledge about the 
structures and enzymology of helminth enzymes lags substantially behind that for humans and other 
well-studied species.  In particular, detailed comparative studies between parasite and host enzymes 
are relatively rare.  However, the identification of subtle differences in structure, mechanism or 
other biochemical properties may reveal aspects which could be targeted in the design of inhibitors 
specific to parasite proteins. 
The first committed step in glycolysis is catalysed by hexokinase (EC 2.7.1.1).  RNAi, overexpression 
and enzymological studies have validated this enzyme as a target in Trypanosoma brucei.  In this 
organism, a 60% reduction in hexokinase activity resulting from silencing the corresponding gene by 
RNAi was sufficient to kill the parasite [92].  Sequencing of hexokinase from Haemonchus contortus 
revealed two insertions (compared to the human sequence) located on the surface of the enzyme 
which were suggested as possible sites that could be targeted by inhibitors [93].  However, no 
biochemical work has been done to follow up this proposal.  Brugia malayi hexokinase is tetrameric 
(compared to the monomeric and dimeric forms more commonly seen in mammals) and has 
different kinetic parameters to the human enzyme [94, 95].  S. mansoni hexokinase is inhibited by 5-
thio-D-glucose (Scheme 3) [96].  However, this compound also inhibits mammalian hexokinase [82].  
Modified monosaccharides have been suggested as general inhibitors or antimetabolites targeting 
hexokinase [97]; however, little work has been done to exploit this suggestion with hexokinases 
from helminth parasites. 
Glucose 6-phosphate isomerase (phosphoglucose isomerase; EC 5.3.1.9) catalyses the conversion of 
glucose 6-phosphate to fructose 6-phosphate.  In the cestode Echinococcus multilocularis, the 
enzyme is involved in pathogen-host interactions as well as glycolysis.  In order to interact with the 
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host, the enzyme must be released from the cells and, as a consequence, host animals develop an 
immune response towards the enzyme [98].  This dual role suggests that antagonism of the 
enzyme’s actions may disrupt both the energy metabolism of the organism and the interaction with 
the host.  Sugar phosphates (and related compounds) inhibit S. mansoni glucose 6-phosphate 
isomerase; 5-phospho-D-arabinonate (Scheme 3) was the most potent inhibitor tested [99].  
However, this compound also inhibits the human enzyme to a similar extent [100]. 
Phosphofructokinase is a proven target of trivalent antimonials (see above).  In the filarial parasite 
Setaria cervi, the enzyme may act as a secondary target for the anthelminthic suramin (Scheme 3) 
[101].  The enzyme has been characterised from a number of other species, including the nematodes 
Teladorsagia circumcincta [102] and A. suum [103, 104], the trematode F. hepatica [105-107] and 
the cestode Hymenolepis diminuta [108].  To date, no compounds have been identified which mimic 
the worm clearing effectiveness of the trivalent antimonials but lack the side-effects.  A similar 
picture emerges for aldolase (EC 4.1.2.13), the enzyme which catalyses the splitting of fructose 1,6-
bisphosphate.  Aldolase from the filarial nematode Onchocerca volvulus is secreted from the 
organism and induces an immune response in the host [109].  The enzyme from a number of 
helminths including S. mansoni, A. suum, Heterodera glycines and Globodera rostochiensis has also 
been characterised [110-112].  The viability of the plant parasitic nematode Heterodera glycines is 
reduced when the organism infects genetically modified plants which express RNAi targeted against 
its aldolase gene [113], thus demonstrating that this enzyme has potential as a drug target. 
Triose phosphate isomerase (TPI; EC 5.3.1.1) catalyses the interconversion of glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate, thus ensuring that all six carbon atoms from glucose 
are ultimately converted to pyruvate by glycolysis.  TPI from the cestode Taenia solium shows few 
biochemical differences from the enzyme from one of the parasite’s main hosts, the pig [114, 115].  
This enzyme can be noncompetitively inhibited by antibodies (and Fab fragments derived therefrom) 
raised against it [116].  TPI from the trematodes F. hepatica and S. mansoni have both been 
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biochemically characterised [117, 118].  Phosphoenolpyruvate (Scheme 3) is an inhibitor of F. 
hepatica TPI; this inhibition is approximately 10-fold weaker than observed with the human enzyme 
[117, 119]. The structures of the enzyme from both species have been modelled and the S. mansoni 
enzyme contains a small loop on the surface (Ser-157 to Asp-159) which is not present in the human 
enzyme; this may be a site for immune recognition of the parasite enzyme [118, 120].  Otherwise, 
the fluke enzymes show high predicted structural similarity to the human ones [117, 118].  In a 
number of unicellular parasites, covalent modification of TPI at surface-exposed cysteine residues 
has proved to be a successful strategy for the identification of species-specific TPI inhibitors [121-
128].  One of these residues is conserved in S. mansoni TPI (as Cys-221), suggesting that there is 
potential for a similar approach.  An alternative strategy, which has also been employed in 
unicellular parasites, has been to discover reagents which disrupt the dimer interface [129-131].  
This may also have potential in parasitic helminths.  TPI is externalised in a number of species and 
may play a role in host-parasite interactions.  As such it has attracted attention as a vaccine 
candidate; for examples, see [132-135]. 
Glyceraldehyde 3-phosphate is oxidised and phosphorylated in a reaction catalysed by 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12).  Interestingly, RNAi knockdown 
of the GAPDH gene in S. mansoni resulted in no detectable phenotypic changes.  This was ascribed 
to metabolic plasticity of the organism [136].  Alternatively, it is possible that the protein product 
has a relatively long half-life in the organism and so GAPDH activity was not greatly affected by 
reduction in mRNA levels.  The GAPDH from H. contortus is highly stable, both to thermal 
denaturation and pH [137].  The enzyme from F. hepatica behaves differently.  In the absence of 
bound ligands, the enzyme is relatively unstable towards thermal denaturation but addition of 
glyceraldehyde 3-phospate substantially increases the protein’s stability [138].  GAPDH from F. 
hepatica also has interesting oligomeric properties.  Addition of either glyceraldehyde 3-phosphate 
or NAD+ shifts the tetramer-dimer equilibrium towards the dimer.  The mammalian enzyme 
undergoes a similar transition, but both substrates are required [138, 139].  The dimeric form of the 
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rabbit enzyme is inactive as a dehydrogenase [139].  Further investigations are required to 
determine if the dimeric form of the F. hepatica enzyme is active.  If, like the rabbit enzyme, it 
proves not to be, reagents which promote or stabilise the dimeric form over the tetramer may 
represent a potential strategy for antagonism of GAPDH activity in the parasite.  GAPDH from S. 
mansoni is recognised and inhibited by antisera from infected animals [140].  It is one of the antigens 
recognised by humans who are more resistant to infection by the parasite [141].  Thus, GAPDH is 
also externalised by the parasite and may have some potential as a vaccine candidate [142-146].  In 
H. contortus, GAPDH interacts with the C3 complement subunit, inhibiting its function [147].  
Antagonism of this interaction may also be a fruitful strategy for chemotherapy. 
The first production of ATP in glycolysis is catalysed by the enzyme phosphoglycerate kinase.  
Vaccination with F. hepatica phosphoglycerate kinase gave some protection against infection which 
was ascribed to blockage of the fluke’s energy metabolism [148].  However, no direct evidence of 
enzyme inhibition has been obtained to date.  It is equally probably that the protection following 
vaccination results from the disruption of some interaction between surface-expressed enzyme and 
the host.  A tegumental location for the enzyme in Clonorchis sinensis supports the latter hypothesis 
[149].  In most eukaryotes, phosphoglyceromutase requires a tightly bound 2,3-bisphospho-D-
glycerate cofactor.  However, nematodes have a cofactor-independent phosphoglyceromutase (EC 
5.4.2.12) [150].  In addition to the cofactor requirement the two types of phosphoglyeromutase 
differ in sequence, structure and catalytic mechanism.  The nematode enzyme has attracted 
considerable attention as a potential drug target due to these differences from the host enzyme 
[151-154].  A number of potential inhibitors have been identified by computational chemistry 
methods (Scheme 4); however these have yet to be tested in vitro or in vivo [151].  In the non-
parasitic nematode, Caenorhabditis elegans, RNAi studies have demonstrated that the enzyme is 
essential for viability [150].  However, recent high throughput screening has thrown doubt onto the 
“druggability” of this enzyme.  Although some inhibitors were discovered from the screen (Scheme 
4), there were generally of relatively low affinity (IC50>10 μM) [155].  Trematodes and cestodes have 
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cofactor-dependent (i.e. host-like) phosphoglyceromutases and relatively few of these enzymes 
have been characterised; one exception is the enzyme from C. sinensis [156].  It is an interesting 
paradox that the host-like enzymes in F. hepatica can be successfully and selectively inhibited by 
Clorsulon (see above), yet there appears to be issues with the druggability of the unusual nematode 
enzymes.  This suggests that even subtle differences between host and parasite enzymes can be 
exploited and that, perhaps, the search for novel molecules which inhibit trematode and cestode 
phosphoglycerate kinase and/or phosphoglycerate mutase should be intensified. 
Like the majority of glycolytic enzymes, enolase (EC 4.2.1.11), is externalised in many parasitic 
helminths and may play a role in host-pathogen interactions, particularly those involving the blood 
clotting system.  Consequently the majority of efforts have focussed on testing the enzyme’s 
potential as a vaccine candidate [157-166].  Silencing of the enolase gene in C. sinensis by RNAi 
resulted in significantly decreased survival of the worms, suggesting that the protein has potential as 
a drug target [167].  A modest reduction in survival (approximately 20%) was seen in similar 
experiments in A. suum [168].  In S. mansoni, enolase is a binding partner of the antimalarial drug 
mefloquine (Lariam; Scheme 3) [169].  This drug has some potential for the treatment of 
schistosomiasis and it is possible that enolase is a pharmacologically important target [169-171].  
Interestingly, the mode of action in the malarial parasite is not well defined.  The drug is believed to 
interact with haem (or its precursors) or to inhibit one of the enzymes involved in the synthesis if 
haem, possibly haem polymerase [172-175]. 
The final reaction of glycolysis results in the second generation of ATP and is catalysed by pyruvate 
kinase (EC 2.7.1.40).  Where phosphoenolpyruvate is used to generate oxaloacetate (see above) this 
reaction is omitted and the helminth pyruvate kinases are relatively understudied.  The F. hepatica 
Moniezia expansa and Dicrocoelium dendriticum enzymes display positive cooperativity towards 
phosphoenolpyruvate and are inhibited by malate (Scheme 3) [176-178].  Malate inhibition does not 
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appear to have been detected in the mammalian enzyme.  Since pyruvate kinase is unlikely to be 
active for the anaerobic parts of the parasite’s life cycle its potential as a drug target may be limited. 
 
Tricarboxylic acid cycle and oxidative phosphorylation:  current state of knowledge 
Glycolysis and the TCA are linked by a reaction catalysed by pyruvate dehydrogenase enzyme 
complex (EC 1.2.4.1, EC 2.3.1.12 and EC 1.8.1.4).  Pyruvate is oxidatively decarboxylated generating 
carbon dioxide, acetyl coenzyme A and NADH.  The complex from A. suum has been extensively 
characterised [179-185].  The pyruvate dehydrogenase complex (PDC) is inactivated by 
phosphorylation (catalysed by pyruvate dehydrogenase kinase, EC 2.7.11.2) in higher eukaryotes 
[186].  However, it appears that this inactivation is more subtle and graded in A. suum.  Whereas a 
single phosphorylation can result in complete inactivation in the human PDC, a greater degree of 
phosphorylation is required for inactivation in A. suum [187, 188].  This enables the complex to 
retain some activity even under relatively anaerobic conditions.  In general, cestode PDCs are less 
sensitive to inhibition by NADH than those from aerobic organisms, including their hosts [179, 189].  
Similarly the activation of pyruvate dehydrogenase kinase by increased NADH levels is less in 
cestodes compared to mammals [190, 191]. 
Compared to the glycolytic enzymes, the TCA enzymes from helminth parasites have, in general, 
received less attention.  A recent gene knockdown study has shown that down-regulation of the 
genes encoding citrate synthase (EC 2.3.3.1), aconitase (EC 4.2.1.3) and malate dehydrogenase block 
mitosis in C. elegans suggesting that selective inhibition of this pathway may be viable in the 
treatment of nematode infections [192].  An initial characterisation of citrate synthase from F. 
hepatica has been carried out, but this was hampered by difficulties in purifying the recombinant 
protein [193].  Mammalian α-ketoglutarate dehydrogenase (EC 1.2.4.2) is up-regulated by calcium 
ions, but the enzyme from F. hepatica is not [194, 195].  The precise molecular nature and 
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mechanisms of this difference has not been elucidated, nor has it been exploited in the discovery of 
selective inhibitors.  Fumarase (EC 4.2.1.2) from A. suum has been recombinantly expressed and 
purified in good yield, but no inhibitors of this enzyme have been reported [196].  Similarly, 
recombinant mitochondrial malate dehydrogenase from C. sinensis has been produced and partially 
characterised[197, 198].  4,4'-Bisdimethylaminodiphenylcarbinol (Michler's hydrol; Scheme 5) 
inhibits the mitochondrial enzyme from this species but not the cytoplasmic isoform [198].  The 
mechanism of this inhibition has not been determined.  Filarin (vinorelbine; Scheme 5), a cancer 
chemotherapeutic synthesised from precursors derived from the rosy periwinkle Catharanthus 
roseus, inhibits malate dehydrogenase from the filarial worm, Setaria digitata [199]. 
 
Other metabolic pathways 
Some other metabolic pathways have received attention over the years.  Of particular interest is the 
“shunt” which links cytoplasmic phosphoenolpyruvate to mitochondrial oxaloacetate.  
Phosphoenolpyruvate-carboxykinase (PEPCK; EC 4.1.1.32) catalyses the first step of this shunt.  The 
enzyme from the cestode Raillietina echinobothrida is activated by a variety of plant extracts [200].  
PEPCK from another cestode, Hymenolepis diminuta, is inhibited by α-ketoglutarate (Scheme 6) 
[201].  The mammalian enzyme is also inhibited by this TCA intermediate [202]. 
Nafuredin (Scheme 6) inhibits mitochondrial complexes I and II in helminths.  When assayed against 
complex I it competed with rhodoquinone.  It demonstrated anthelminthic activity against H. 
contortus in trials with experimentally infected sheep and against mice infected with the cestode 
Hymenolepis nana [203].  A related γ-lactone compound nafuredin-γ (Scheme 6) also has activity 
against complex I [204].  E. multilocularis complex I is inhibited by quinazoline (Scheme 6) and this 
compound kills the parasite [205].  This compound, and its derivatives, also inhibit mammalian 
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mitochondrial complex I [206].  So, the challenge would be to identify derivatives which selectively 
inhibit the complex from helminths. 
The Leloir pathway converts galactose into the glycolytic intermediate glucose 6-phosphate.  This 
pathway is essential in unicellular parasites from the genus Trypanosoma since they are unable to 
take up galactose from the environment and rely on “reversing” some of the Leloir pathway 
reactions in order to generate galactose for glycoprotein synthesis [207-211].  Thus, inhibition of 
GALE in these species has potential for the development of novel therapeutics [212-215].  Six 
inhibitors of F. hepatica UDP-galactose 4-epimerase (EC 5.1.3.2) have been identified; two showed 
good selectivity over the human enzyme [216].  These compounds were 5-fluoroorotate (5-FOA) and 
a peptide derivative, N-[(benzyloxy)carbonyl]leucyltryptophan (Scheme 6).  Interestingly, orotate 
(which differs from 5-FOA only by the absence of the fluorine atom) demonstrated essentially no 
selectivity between the human and parasite enzymes.  This loss of selectivity arises from two factors:  
a 20-fold drop in the affinity for the fluke enzyme and 50-fold increase in the affinity for the human 
one [216].  The rationale for targeting GALE was based on the devastating symptoms of severe forms 
of GALE deficiency (type III galactosemia) in humans [217].  However, it remains to be formally 
demonstrated that targeting the enzyme in helminth parasites will result in sufficient levels of 
impairment.  Unlike in trypanosomes, there is no evidence that the enzyme is essential for the 
production of galactose.  However, the tegument of many helminths contains complex glycoproteins 
and it is likely that the disruption of the Leloir pathway would lead to alterations in this structure 
potentially altering parasite-host interactions [218-226].  Like many of the glycolytic enzymes, GALE 
may also have potential as a vaccine against helminth infections [227]. 
Carnitine palmitoyl transferase 1 (CPT1; EC 2.3.1.21) is a key enzyme in the transfer of fatty acids 
into the mitochondria prior to their β-oxidation.  Inhibition of CPT1 in S. mansoni by etomoxir 
(Scheme 6) resulted in complete inhibition of egg production [228].  Etomoxir inhibits CPT1 in a 
variety of species, including humans [229].  The etomoxir treated worms themselves remained 
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viable, although with decreased oxygen consumption resulting from lower rates of oxidative 
phosphorylation [228].  Thus, it can be concluded that oxidative phosphorylation of NADH resulting 
from β-oxidation of fatty acids is essential for egg production in this species.  Blocking this process 
may have value in breaking infection cycles and reducing the pathological effects associated with egg 
production.  However, it seems unlikely that it would kill adult worms. 
Arginase (EC 3.5.3.1) from S. mansoni is a rare example of a helminth metabolic enzyme for which 
the crystal structure in the presence of an inhibitor is known [230].  The enzyme catalyses the 
hydrolysis of arginine to produce urea and ornithine.  In helminths, this reaction is thought to be 
important in proline biosynthesis [231].  It has also been hypothesised that it reduces the amount of 
arginine in the parasite.  Doing so may assist in immune evasion since arginine is a key precursor of 
nitric oxide (NO) which is produced in macrophages and stimulates the cytotoxic activities of these 
cells [232, 233].  A druggable region of the protein has been identified and this site can 
accommodate a range of amino acid-like molecules [230].  Of particular interest is a cleft in this 
region which can accommodate substituents on the α-carbon of amino acids.  This enables the 
protein to bind to α,α-disubstituted amino acids, such as (R)-2-amino-6-borono-2-[2-(piperidin-1-
yl)ethyl]hexanoic acid (Scheme 6).  The cleft in the S. mansoni enzyme is more non-polar than the 
equivalent cleft in the human enzyme and it has been suggested that species specific reagents could 
be designed by exploiting this fact [230]. 
 
Unmet research needs[U1] 
Fundamental research on parasitic helminths is limited in compared to fields such as cancer, heart 
disease or HIV research.  This results in a relatively small knowledge base to exploit in the discovery 
of novel therapeutics.  Despite differences in metabolic pathways being elucidated in the 1970s and 
1980s, few attempts have been made to exploit these in drug discovery.  The number of crystal 
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structures of helminth proteins is small.  Although there has been some successful inhibitor 
discovery based on molecular models (e.g. [216]), experimental structures are generally considered 
superior to models.  Homology models, by their nature, are based on known structures.  Thus, while 
they predict the overall fold very well, they are poor at estimating the structures of regions of the 
protein which differ markedly from the templates.  Yet it is these very differences that may provide 
the key to the design of reagents which specifically inhibit helminth enzymes.  Therefore, a[U2] 
critical research need is a larger number of experimental structures of helminth metabolic enzymes. 
While it may be self-evident to biochemists that disrupting central carbon metabolism pathways 
(especially, perhaps, glycolysis) is highly likely to result in death of the organism, drug discovery 
scientists may require more convincing.  Therefore, experiments demonstrating the vital nature of 
key metabolic enzymes are required.  Although RNAi is often considered to be the “gold standard” in 
such experiments, a note of caution should be sounded.  RNAi reduces the amount of mRNA 
transcript for a specific gene:  it has not direct effect on the levels of protein.  Protein concentrations 
will only decrease as the molecules are degraded and not replaced (since there is no mRNA).  
Metabolic enzymes are typically long-lived and may, therefore, persist for days (or longer) in the cell 
[234].  Therefore, lack of a phenotype after only a few days’ exposure to RNAi is not conclusive 
evidence that the protein is not vital.  In such experiments it will be necessary to verify that protein 
levels are depleted (through activity assays or western blotting).  Long exposures to the RNAi may 
also be necessary and, in some cases, this may not be practical.  If so, alternative approaches may be 
necessary such as enzyme inhibition in vivo.  This may require us to rediscover the “old” literature:  
the discovery of many metabolic pathways relied, in part, on the use of specific enzyme inhibitors 
(for a famous example, see [235]). 
Since single point inhibition of pathways can result in compensatory mechanisms within the cell, it 
may be better to consider pathways as a whole.  Thus the development of systems biology 
approaches to helminth metabolism is desirable.  Much of the data to build the models already 
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exists.  Many helminth metabolic enzymes were purified from native sources in the 1970s and 1980s 
and their kinetic parameters determined.  This is complemented by more recent data derived from 
studies on recombinant proteins. 
The anaerobic metabolism of many helminths relies on the partial reversal of the TCA and the use of 
rhodoquinone in a modified electron transport pathway (Figure 1; Scheme 2).  A greater 
understanding of this process, in particular the synthesis of rhodoquinone would be useful.  
Targeting the synthesis of rhodoquinone (which does not occur in the host) would, in theory, 
prevent this anaerobic electron transport without damaging the host. 
Ultimately, if existing knowledge and new work is to lead towards new drugs to treat helminth 
infections, selective inhibitors need to be discovered.  This is likely to come from a combination of 
high throughput screening and computational chemistry approaches.  However, as in other 
therapeutic areas, it is likely that the majority of inhibitors discovered will be useless as drugs.  Either 
the compounds will fail to penetrate cells (and thus never have the opportunity to bind to the 
target) or they will prove equally toxic to the host and parasite.  In the majority of helminths, the 
only way to test the efficacy of compounds is on live worms in culture or on artificially infected 
animals.  Ideally, cell culture systems would be available to enable intermediate stage testing and a 
relatively low cost method to eliminate some compounds before proceeding to more complex test 
systems.  Thus, the development of parasitic helminth cell culture systems is another significant, 
unmet research need. 
 
Conclusions 
Inhibition of metabolic pathways in parasitic helminths would, almost certainly, result in reduced 
growth or death of the pathogen.  The major challenges are a relative lack of knowledge about the 
biochemistry of the enzymes involved and the (perceived) difficulty of discovering reagents which 
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are selective for parasite enzymes over the host ones.  In this respect, the case of 
phosphoglyceromutase (described above) represents a cautionary tale.  The nematode enzyme has 
many features of an “ideal” drug target.  It is likely to be essential to the organism, it is readily 
assayable in vitro and, critically, it differs in structure, sequence and mechanism from the host 
enzyme.  In theory, compounds which block this enzyme’s activity should kill the helminth without 
affecting the host[U3].  Yet, a recent study considered the enzyme to be “undruggable” [155].  In 
contrast, the trematode phosphoglyceromutase is similar in sequence (and, therefore, presumably 
structure and mechanism) to the mammalian enzyme.  This enzyme is a target of the anthelminthic 
drug Clorsulon[U4] [51].  If this tale teaches us anything, it is that sometimes dogma should be 
avoided and that there may be merit in attempting to find the next Clorsulon, i.e. a selective 
inhibitor of a parasitic helminth metabolic enzyme. 
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Figure and scheme legends 
Figure 1:  Schematic diagram of the metabolism of helminths under anaerobic conditions.  CoA, 
coenzyme A; AcCoA, acetyl coenzyme A; MeMalCoA, methylmalonyl coenzyme A; PropCoA, 
propionyl coenzyme A; RQ, rhodoquinone; RQH, reduced rhodoquinone.  The grey shaded box 
represents mitochondrial membrane complex I, the dashed line transport of malate across the 
mitochondrial membranes and the large, open arrow the tranlocation of protons between the 
matrix and the intermembrane space of the mitochondria.  The outward translocation by complex I 
generates a proton motive force which can be utilised by ATP synthase (grey circle; EC 3.6.3.14) to 
generate ATP. 
Scheme 1:  Structures of drugs known to target helminth metabolic enzymes 
Scheme 2:  Structure of rhodoquinone 
Scheme 3:  Structures of inhibitors of helminth glycolytic enzymes 
Scheme 4:  Structures of experimentally and computationally identified inhibitors of nematode 
phosphoglycerate mutase 
Scheme 5:  Structures of inhibitors of helminth TCA and oxidative phosphorylation enzymes 
Scheme 6:  Structures of inhibitors of helminth β-oxidation, Leloir pathway and amino acid 
metabolism pathways 








